Atossa Therapeutics (ATOS) Non-Current Debt (2013 - 2015)

Atossa Therapeutics (ATOS) posted quarterly Non-Current Debt of $12531.0 for Q2 2015, down 50.33% quarter-over-quarter from $25230.0 in Q1 2015.

Atossa Therapeutics (ATOS) Non-Current Debt (2013 - 2015) Analysis & Trends

Atossa Therapeutics (ATOS) has reported Non-Current Debt for 3 consecutive years, with $12531.0 the latest figure, recorded in Q2 2015.

In Q2 2015, Non-Current Debt changed N/A year-over-year to $12531.0; the TTM figure through Jun 2015 stood at $12531.0 (changed N/A YoY), while the FY2014 annual figure was $49216.0, up 745.64% from the prior year.
Non-Current Debt retreated to $12531.0 in Q2 2015 per ATOS's latest filing, from $25230.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $49216.0 in Q4 2014 and bottomed at $5820.0 in Q4 2013.
Historically, Non-Current Debt has averaged $23199.2 across 3 years, with a median of $18880.5 in 2015.
On a YoY basis, Non-Current Debt climbed as much as 745.64% in 2014 and fell as far as 745.64% in 2014.
Atossa Therapeutics' Non-Current Debt stood at $5820.0 in 2013, then jumped by 745.64% to $49216.0 in 2014, then plunged by 74.54% to $12531.0 in 2015.
Business Quant data shows ATOS's Non-Current Debt at $12531.0 in Q2 2015, $25230.0 in Q1 2015, and $49216.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	Atossa Therapeutics	22.63 Mn	22.63 Mn	-	-

Download Data